Table 1. Characteristics of HIV-infected patients receiving ART, by cotrimoxazole prophylaxis.
| Variable | Total n (%) | Non-CTX group n (%) | CTX group n (%) | χ2/Z | p |
|---|---|---|---|---|---|
| Age at ART initiation | 9.924 | 0.042 | |||
| <30 | 502 (14.94) | 102 (16.69) | 400 (14.56) | ||
| 30–39 | 1,005 (29.92) | 182 (29.79) | 823 (29.95) | ||
| 40–49 | 766 (22.80) | 124 (20.29) | 642 (23.36) | ||
| 50–59 | 571 (17.00) | 91 (14.89) | 480 (17.47) | ||
| ≥60 | 515 (15.33) | 112 (18.33) | 403 (14.67) | ||
| Gender | 11.198 | 0.001 | |||
| Male | 2,520 (75.02) | 426 (69.72) | 2,094 (76.20) | ||
| Female | 839 (24.98) | 185 (30.28) | 654 (23.80) | ||
| Marital status | 0.348 | 0.931 | |||
| Single, divorced or widowed | 1,019 (30.34) | 183 (29.95) | 836 (30.42) | ||
| Married or cohabitation | 2,336 (69.54) | 428 (70.05) | 1,908 (69.43) | ||
| Unknown | 4 (0.12) | 0 | 4 (0.15) | ||
| Route of HIV transmission | 11.08 | 0.004 | |||
| Blood or plasma transfusion | 232 (6.91) | 53 (8.67) | 179 (6.51) | ||
| Sexual transmission | 3,062 (91.16) | 538 (88.05) | 2,524 (91.85) | ||
| Other/unknown | 65 (1.94) | 20 (3.27) | 45 (1.64) | ||
| Baseline CD4 cell count (cells/μL) | 106.83 | <0.001 | |||
| <50 | 1,755 (52.25) | 228 (37.32) | 1,527 (55.57) | ||
| 50–99 | 658 (19.59) | 109 (17.84) | 549 (19.98) | ||
| 100–199 | 946 (28.16) | 274 (44.84) | 672 (24.45) | ||
| WHO clinical stage | 156.7 | <0.001 | |||
| I | 628 (18.70) | 201 (32.90) | 427 (15.54) | ||
| II | 335 (9.97) | 62 (10.15) | 273 (9.93) | ||
| III | 665 (19.80) | 159 (26.02) | 506 (18.41) | ||
| IV | 1,731 (51.53) | 189 (30.93) | 1,542 (56.11) | ||
| Baseline body mass index, kg/m2 | 6.764 | 0.034 | |||
| <18.5 | 1,015 (34.90) | 180 (31.49) | 835 (35.74) | ||
| 18.5–23.9 | 1,652 (56.81) | 332 (58.04) | 1,320 (56.51) | ||
| ≥24.0 | 241 (8.29) | 60 (10.49) | 181 (7.75) | ||
| Initial ART regimen | 51.284 | <0.001 | |||
| NRTI + NNRTI | 3,108 (92.53) | 525 (85.92) | 2,583 (94.00) | ||
| NRTI + PI | 229 (6.82) | 82 (13.42) | 147 (5.35) | ||
| Others | 22 (0.65) | 4 (0.65) | 18 (0.66) | ||
| Duration of follow-up (years)* | 2.47 (0.82–5.07) | 2.40 (1.09–3.49) | 2.49 (0.78–5.44) | −3.43 | 0.001 |
| Delayed time to ART initiation (months)* | 1.00 (1.00–3.00) | 1.00 (1.00–5.00) | 1.00 (1.00–2.00) | −4.77 | <0.001 |
*Data are presented as medium ± interquartile range (IQR), and non-parametric tests were used to compare the characteristics between the two groups.